Revista Española de Cardiología (English Edition) Revista Española de Cardiología (English Edition)
Rev Esp Cardiol. 2006;59:807-15 - Vol. 59 Num.08 DOI: 10.1016/S1885-5857(07)60046-2

Health Economic Evaluation of Low-Dose Acetylsalicylic Acid in the Primary Prevention of Cardiovascular Disease

Mark Lamotte a, Carme Piñol b, Carlos Brotons c, Lieven Annemans d, Elena Guardiola b, Thomas Evers e, Maria Kubin e

a Health Economics and Disease Management Unit, IMS Health, Brussels, Belgium.
b Q.F. Bayer SA, Barcelona, Spain.
c Unidad de Investigación, EAP Sardenya, Servei Català de la Salut, Barcelona, Spain.
d Health Economics and Disease Management Unit, IMS Health, Brussels, Belgium. Universidad de Gant, Gant, Belgium.
e Bayer Healthcare AG, Wuppertal, Germany.

Keywords

Aspirin. Primary prevention. Cost. Health economic evaluation. Cardiovascular disease.

Abstract

Introduction and objectives. Low-dose aspirin is standard treatment for patients with a history of cardiovascular disease. Its use in primary prevention is more controversial. However, recent studies also support the use of aspirin in high-risk individuals with no history of cardiovascular disease. This study investigated the health economic implications of using low-dose aspirin in the primary prevention of cardiovascular disease in Spain. Methods. A model was developed to predict the cost-effectiveness of low-dose aspirin in the primary prevention of cardiovascular disease over a period of 10 years. The direct costs used were those of the Spanish National Health Service (NHS). Results were expressed as cost per life-year gained and per quality-adjusted life-year gained. Results. Administering low-dose aspirin to an individual with a 10-year risk of coronary heart disease ≥15% resulted in an average net saving of e 797 (95% CI, e 263-1331) over the 10-year period, with savings starting in the first year. For an annual risk ≥0.24%, this form of treatment would reduce NHS costs. Treating all at-risk individuals in the Spanish population with aspirin would save e 26.5 million from the healthcare budget, starting in the first year. Conclusions. Administering low-dose aspirin to individuals with a 10-year risk of coronary heart disease ≥15% would result in significant cost savings for the Spanish NHS. Sensitivity analysis confirmed the robustness of these findings.

1885-5857/© 2006 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved

Cookies
x
To improve our services and products, we use cookies (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.
Cookies policy
x
To improve our services and products, we use cookies (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.